Stay updated with breaking news from Marc Forth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AEON Biopharma, Inc. (AEON) announced Wednesday a workforce reduction by approximately 55% as part of its strategic reprioritization and cost reduction plan. The company has terminated Peter Reynolds as the chief financial officer, principal financial officer and principal accounting officer, effective as of May 17, under its cash preservation strategy.
Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over placebo. Despite anticipated reductions in monthly migraine days, statistical significance was not reached, prompting a review of development strategies and financial measures.
– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive...
– Expect to announce topline data in Q3 2024 –– Company plans in Q1 2024 an end-of-phase 2 meeting with the FDA to discuss the Phase 3 program in ...
– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study – – Ongoing Phase 2